Imugene Ltd has released a press release.
Imugene receives $1.3m R&D Tax Refund
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Imugene
- Imugene successfully completes preclinical animal studies
- Imugene Final Cancer Vaccine Doses Delivered to GMP Depot
- Imugene Receives Approval to Start Gastric Cancer Study
- Imugene Receives Institutional Review Board approval
- Regulatory package submission for Her-Vaxx in Hong Kong
Later from Imugene
- Imugene Share Placement raises $3.2 million
- Imugene Commences HER-Vaxx Phase 1b/2 Gastric Cancer Study
- Leslie Chong Appointed Chief Executive Officer
- Acquisition of immuno-oncology technology
- Response to ASX Aware Query
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene